The Experts below are selected from a list of 5160 Experts worldwide ranked by ideXlab platform

Ahlam Jeragh - One of the best experts on this subject based on the ideXlab platform.

  • Assessment of Immune Status Against Measles, Mumps, and Rubella in Young Kuwaitis: MMR Vaccine Efficacy
    2020
    Co-Authors: Nada Madi, Haya Altawalah, Wadha Alfouzan, Widad Al-nakib, Ebtehal Al-roumi, Ahlam Jeragh
    Abstract:

    Seroprevalence studies on measles, mumps and rubella IgG antibodies after the implementation of measles-mumps-rubella (MMR) Vaccine are lacking in Kuwait. This research is an age-stratified serological study to assess the herd immunity to measles, mumps and rubella among the young Kuwaiti population to evaluate the effectiveness of the MMR Vaccine. IgG antibody titers to mumps, measles, and rubella were determined with commercial immune-assay in serum samples of 1000 Kuwaitis aged 5-20 years. The highest level of seropositivity was to measles (94.6%), which was significantly higher in females than in males. The highest seronegativity was for mumps (29%). The percentage of the young Kuwaiti population who were serologically positive for all the component of the MMR Vaccine was 47%, and 2% of the individuals were without any protective antibodies to measles, mumps and rubella.  Females aged 5-10 years were best protected to rubella; however, seronegativity in 8.2% of 11-20-year-old females makes them vulnerable to rubella virus infection and congenital complications during pregnancy. The study provided insight into the effect of the MMR Vaccine on seroprevalence of antibodies against measles, mumps and rubella in Kuwait, which will contribute to the global knowledge base of Vaccine coverage and help to inform elimination strategies. The findings strengthen the need for a third dose of MMR Vaccine and catch-up campaigns for the young Kuwaiti population to increase vaccination coverage and prevent waning immunity, especially among those who received only one dose of the Vaccine during childhood.

  • Assessment of immune status against measles, mumps, and rubella in young Kuwaitis: MMR Vaccine efficacy.
    Journal of medical virology, 2020
    Co-Authors: Nada Madi, Haya Altawalah, Wadha Alfouzan, Widad Al-nakib, Ebtehal Al-roumi, Ahlam Jeragh
    Abstract:

    Seroprevalence studies on measles, mumps, and rubella immunoglobulin G (IgG) antibodies after the implementation of the measles-mumps-rubella (MMR) Vaccine are lacking in Kuwait. This study is an age-stratified serological study to assess the herd immunity to measles, mumps, and rubella among the young Kuwaiti population to evaluate the effectiveness of the MMR Vaccine. IgG antibody titers to mumps, measles, and rubella were determined with commercial immune-assay in serum samples of 1000 Kuwaitis aged 5 to 20 years. The highest level of seropositivity was to measles (94.6%), which was significantly higher in females than in males. The highest seronegativity was for mumps (29%). The percentage of the young Kuwaiti population who were serologically positive for all the components of the MMR Vaccine was 47%, and 2% of the individuals were without any protective antibodies to measles, mumps, and rubella. Females aged 5 to 10 years were best protected to rubella; however, seronegativity in 8.2% of 11- to 20-year-old females makes them vulnerable to rubella virus infection and congenital complications during pregnancy. The study provided insight into the effect of the MMR Vaccine on seroprevalence of antibodies against measles, mumps, and rubella in Kuwait, which will contribute to the global knowledge base of Vaccine coverage and help to inform elimination strategies. The findings strengthen the need for a third dose of MMR Vaccine and catch-up campaigns for the young Kuwaiti population to increase vaccination coverage and prevent waning immunity, especially among those who received only one dose of the Vaccine during childhood.

Helen Bedford - One of the best experts on this subject based on the ideXlab platform.

  • MMR Vaccine and autism
    BMJ (Clinical research ed.), 2010
    Co-Authors: Helen Bedford, David Elliman
    Abstract:

    Health professionals must enter the public arena if future debacles are to be prevented Two and a half years after beginning to hear evidence, the General Medical Council (GMC) has ruled that three researchers acted improperly in the conduct of their research into a proposed new syndrome of autistic enterocolitis.1 It is 12 years since publication of the study in the Lancet , which has now been retracted, described the research to which the hearing relates.2 Subsequent events have had a major impact on children’s health. The paper described 12 children with a pervasive developmental disorder and bowel disease, which, the authors suggested, was a new syndrome. In eight of the children, symptoms were reported to have started soon after receipt of the measles, mumps, and rubella (MMR) Vaccine. In their conclusions, they stated, “we did not prove an association between measles, mumps and rubella Vaccine and the syndrome described” and that more research was needed. However, at a press conference, one of the authors suggested that, rather than using the combined MMR Vaccine, single Vaccines for measles, mumps, and rubella should be given at yearly intervals. It was this statement, unsupported by the research, that sparked media interest. At the time, the supposed link between MMR and autism was shown to be without substance,3 but it was predicted that this bad publicity could precipitate a Vaccine safety scare that would result in reduced Vaccine …

  • Rubella and the MMR Vaccine.
    Nursing times, 2006
    Co-Authors: Helen Bedford, Pat A Tookey
    Abstract:

    Rubella is often thought of as a disease of childhood that has few complications. However, congenital rubella resulting from transmission from mother to baby during pregnancy can result in multiple severe defects. There are concerns about the uptake of the MMR Vaccine and that any outbreak of rubella would affect disproportionately minority groups in the UK who may not have had the Vaccine. Helen Bedford explains.

  • Should children be given the MMR Vaccine
    Early Years Educator, 2002
    Co-Authors: Helen Bedford, Jonathan Harris
    Abstract:

    What should parents do to protect their children against measles, mumps and rubella? Have the combined MMR Vaccine? Get single Vaccines? Do nothing?

  • Measles, mumps and rubella (MMR) Vaccine
    British Journal of Midwifery, 2002
    Co-Authors: Helen Bedford, David Elliman
    Abstract:

    In the UK, although few immunisations are given to neonates, midwives are asked by some pregnant women and new mothers for their advice about childhood immunisations (Health Promotion England, 2001). Over the last 3–4 years there has been a lot of publicity around the combined measles, mumps and rubella (MMR) Vaccine, much of it adverse and misleading, and so it is likely that mothers will seek views on this Vaccine, in particular, from their midwife.

  • MMR Vaccine—worries are not justified
    Archives of disease in childhood, 2001
    Co-Authors: David Elliman, Helen Bedford
    Abstract:

    The advocates of Vaccination have exalted in the prospect of exterminating the Small Pox from the face of the earth; while its opponents have framed their tales of horror, replete with stories of novel diseases and unheard-of plagues. ... When I consider the many evidences in favour of Vaccination, which the public documents of almost every nation afford, I am at a loss to conceive from what cause such doubts can have arisen; for I think, if an unprejudiced mind will fairly consider the question, it must be convinced that Vaccination has answered the promised end. (from a letter to The Gentleman's Magazine , March 1808, by “Cosmopoliton”) Since the introduction of the measles Vaccine in 1968 and then the measles, mumps, and rubella (MMR) Vaccine in 1988, measles, mumps, and rubella have become rare diseases. However, on the basis of research, primarily from one unit, some parents and health professionals have become concerned about the safety of MMR Vaccine. This has led to a decline in uptake and fears of impending outbreaks.1 In this paper we review the background to these concerns and examine the evidence to date. In the early 1990s the Inflammatory Bowel Disease Study Group (IBDSG) at the Royal Free Hospital in London suggested that measles disease in children predisposed them to inflammatory bowel disease as adults.2 3 However, further research, including that by the IBDSG has shown this not to be so.4-6 Later, the IBDSG suggested that measles vaccination could lead to adult inflammatory bowel disease.7 This study was much criticised at the time8 and further work, including some by the IBDSG, has shown no link.9 10 More recently, Ghosh et al reviewed all the evidence surrounding the presence of measles virus in Crohn's disease and concluded …

Nada Madi - One of the best experts on this subject based on the ideXlab platform.

  • Assessment of Immune Status Against Measles, Mumps, and Rubella in Young Kuwaitis: MMR Vaccine Efficacy
    2020
    Co-Authors: Nada Madi, Haya Altawalah, Wadha Alfouzan, Widad Al-nakib, Ebtehal Al-roumi, Ahlam Jeragh
    Abstract:

    Seroprevalence studies on measles, mumps and rubella IgG antibodies after the implementation of measles-mumps-rubella (MMR) Vaccine are lacking in Kuwait. This research is an age-stratified serological study to assess the herd immunity to measles, mumps and rubella among the young Kuwaiti population to evaluate the effectiveness of the MMR Vaccine. IgG antibody titers to mumps, measles, and rubella were determined with commercial immune-assay in serum samples of 1000 Kuwaitis aged 5-20 years. The highest level of seropositivity was to measles (94.6%), which was significantly higher in females than in males. The highest seronegativity was for mumps (29%). The percentage of the young Kuwaiti population who were serologically positive for all the component of the MMR Vaccine was 47%, and 2% of the individuals were without any protective antibodies to measles, mumps and rubella.  Females aged 5-10 years were best protected to rubella; however, seronegativity in 8.2% of 11-20-year-old females makes them vulnerable to rubella virus infection and congenital complications during pregnancy. The study provided insight into the effect of the MMR Vaccine on seroprevalence of antibodies against measles, mumps and rubella in Kuwait, which will contribute to the global knowledge base of Vaccine coverage and help to inform elimination strategies. The findings strengthen the need for a third dose of MMR Vaccine and catch-up campaigns for the young Kuwaiti population to increase vaccination coverage and prevent waning immunity, especially among those who received only one dose of the Vaccine during childhood.

  • Assessment of immune status against measles, mumps, and rubella in young Kuwaitis: MMR Vaccine efficacy.
    Journal of medical virology, 2020
    Co-Authors: Nada Madi, Haya Altawalah, Wadha Alfouzan, Widad Al-nakib, Ebtehal Al-roumi, Ahlam Jeragh
    Abstract:

    Seroprevalence studies on measles, mumps, and rubella immunoglobulin G (IgG) antibodies after the implementation of the measles-mumps-rubella (MMR) Vaccine are lacking in Kuwait. This study is an age-stratified serological study to assess the herd immunity to measles, mumps, and rubella among the young Kuwaiti population to evaluate the effectiveness of the MMR Vaccine. IgG antibody titers to mumps, measles, and rubella were determined with commercial immune-assay in serum samples of 1000 Kuwaitis aged 5 to 20 years. The highest level of seropositivity was to measles (94.6%), which was significantly higher in females than in males. The highest seronegativity was for mumps (29%). The percentage of the young Kuwaiti population who were serologically positive for all the components of the MMR Vaccine was 47%, and 2% of the individuals were without any protective antibodies to measles, mumps, and rubella. Females aged 5 to 10 years were best protected to rubella; however, seronegativity in 8.2% of 11- to 20-year-old females makes them vulnerable to rubella virus infection and congenital complications during pregnancy. The study provided insight into the effect of the MMR Vaccine on seroprevalence of antibodies against measles, mumps, and rubella in Kuwait, which will contribute to the global knowledge base of Vaccine coverage and help to inform elimination strategies. The findings strengthen the need for a third dose of MMR Vaccine and catch-up campaigns for the young Kuwaiti population to increase vaccination coverage and prevent waning immunity, especially among those who received only one dose of the Vaccine during childhood.

John Whitehall - One of the best experts on this subject based on the ideXlab platform.

  • knowledge attitudes and opinions towards measles and the MMR Vaccine across two nsw cohorts
    Australian and New Zealand Journal of Public Health, 2017
    Co-Authors: Daniel G Brieger, Matthew S Edwards, Poonam Mudgil, John Whitehall
    Abstract:

    Objective: Although the number of national measles cases has greatly decreased since 1980s, there has been resurgence in disease incidence in recent years. While parental knowledge and attitudes toward both disease and vaccinations are known to influence Vaccine uptake, the contribution of these factors toward vaccination rates in NSW populations has not been studied. The aim of this study was to investigate the knowledge and opinions on measles and MMR Vaccine in NSW Central and North Coast regions. Methods: Parents (n=201) of children <12 years were surveyed with a purpose design survey at public beaches at the Central Coast and community markets at the North Coast. Results: Eight per cent of respondents reported not immunising their child with MMR Vaccine. Most respondents recognised that measles is a highly contagious disease. Non-immunisers were found to be older, had a lower perceived severity of measles, were less likely to agree with the efficacy and safety of the Vaccine, and were more likely to have encountered someone who had suffered side-effects of the Vaccine. Conclusions: There is considerable concern over safety of MMR Vaccine among non-immunisers. Implications for public health: Improving confidence in MMR Vaccine should be a target of future public health interventions.

  • Knowledge, attitudes and opinions towards measles and the MMR Vaccine across two NSW cohorts
    Australian and New Zealand journal of public health, 2017
    Co-Authors: Daniel G Brieger, Matthew S Edwards, Poonam Mudgil, John Whitehall
    Abstract:

    Objective: Although the number of national measles cases has greatly decreased since 1980s, there has been resurgence in disease incidence in recent years. While parental knowledge and attitudes toward both disease and vaccinations are known to influence Vaccine uptake, the contribution of these factors toward vaccination rates in NSW populations has not been studied. The aim of this study was to investigate the knowledge and opinions on measles and MMR Vaccine in NSW Central and North Coast regions. Methods: Parents (n=201) of children

David Elliman - One of the best experts on this subject based on the ideXlab platform.

  • MMR Vaccine and autism
    BMJ (Clinical research ed.), 2010
    Co-Authors: Helen Bedford, David Elliman
    Abstract:

    Health professionals must enter the public arena if future debacles are to be prevented Two and a half years after beginning to hear evidence, the General Medical Council (GMC) has ruled that three researchers acted improperly in the conduct of their research into a proposed new syndrome of autistic enterocolitis.1 It is 12 years since publication of the study in the Lancet , which has now been retracted, described the research to which the hearing relates.2 Subsequent events have had a major impact on children’s health. The paper described 12 children with a pervasive developmental disorder and bowel disease, which, the authors suggested, was a new syndrome. In eight of the children, symptoms were reported to have started soon after receipt of the measles, mumps, and rubella (MMR) Vaccine. In their conclusions, they stated, “we did not prove an association between measles, mumps and rubella Vaccine and the syndrome described” and that more research was needed. However, at a press conference, one of the authors suggested that, rather than using the combined MMR Vaccine, single Vaccines for measles, mumps, and rubella should be given at yearly intervals. It was this statement, unsupported by the research, that sparked media interest. At the time, the supposed link between MMR and autism was shown to be without substance,3 but it was predicted that this bad publicity could precipitate a Vaccine safety scare that would result in reduced Vaccine …

  • Measles, mumps and rubella (MMR) Vaccine
    British Journal of Midwifery, 2002
    Co-Authors: Helen Bedford, David Elliman
    Abstract:

    In the UK, although few immunisations are given to neonates, midwives are asked by some pregnant women and new mothers for their advice about childhood immunisations (Health Promotion England, 2001). Over the last 3–4 years there has been a lot of publicity around the combined measles, mumps and rubella (MMR) Vaccine, much of it adverse and misleading, and so it is likely that mothers will seek views on this Vaccine, in particular, from their midwife.

  • MMR Vaccine—worries are not justified
    Archives of disease in childhood, 2001
    Co-Authors: David Elliman, Helen Bedford
    Abstract:

    The advocates of Vaccination have exalted in the prospect of exterminating the Small Pox from the face of the earth; while its opponents have framed their tales of horror, replete with stories of novel diseases and unheard-of plagues. ... When I consider the many evidences in favour of Vaccination, which the public documents of almost every nation afford, I am at a loss to conceive from what cause such doubts can have arisen; for I think, if an unprejudiced mind will fairly consider the question, it must be convinced that Vaccination has answered the promised end. (from a letter to The Gentleman's Magazine , March 1808, by “Cosmopoliton”) Since the introduction of the measles Vaccine in 1968 and then the measles, mumps, and rubella (MMR) Vaccine in 1988, measles, mumps, and rubella have become rare diseases. However, on the basis of research, primarily from one unit, some parents and health professionals have become concerned about the safety of MMR Vaccine. This has led to a decline in uptake and fears of impending outbreaks.1 In this paper we review the background to these concerns and examine the evidence to date. In the early 1990s the Inflammatory Bowel Disease Study Group (IBDSG) at the Royal Free Hospital in London suggested that measles disease in children predisposed them to inflammatory bowel disease as adults.2 3 However, further research, including that by the IBDSG has shown this not to be so.4-6 Later, the IBDSG suggested that measles vaccination could lead to adult inflammatory bowel disease.7 This study was much criticised at the time8 and further work, including some by the IBDSG, has shown no link.9 10 More recently, Ghosh et al reviewed all the evidence surrounding the presence of measles virus in Crohn's disease and concluded …

  • MMR Vaccine worries are not justified
    Archives of Disease in Childhood, 2001
    Co-Authors: David Elliman, Helen Bedford
    Abstract:

    The advocates of Vaccination have exalted in the prospect of exterminating the Small Pox from the face of the earth; while its opponents have framed their tales of horror, replete with stories of novel diseases and unheard-of plagues. ... When I consider the many evidences in favour of Vaccination, which the public documents of almost every nation afford, I am at a loss to conceive from what cause such doubts can have arisen; for I think, if an unprejudiced mind will fairly consider the question, it must be convinced that Vaccination has answered the promised end. (from a letter to The Gentleman's Magazine , March 1808, by “Cosmopoliton”) Since the introduction of the measles Vaccine in 1968 and then the measles, mumps, and rubella (MMR) Vaccine in 1988, measles, mumps, and rubella have become rare diseases. However, on the basis of research, primarily from one unit, some parents and health professionals have become concerned about the safety of MMR Vaccine. This has led to a decline in uptake and fears of impending outbreaks.1 In this paper we review the background to these concerns and examine the evidence to date. In the early 1990s the Inflammatory Bowel Disease Study Group (IBDSG) at the Royal Free Hospital in London suggested that measles disease in children predisposed them to inflammatory bowel disease as adults.2 3 However, further research, including that by the IBDSG has shown this not to be so.4-6 Later, the IBDSG suggested that measles vaccination could lead to adult inflammatory bowel disease.7 This study was much criticised at the time8 and further work, including some by the IBDSG, has shown no link.9 10 More recently, Ghosh et al reviewed all the evidence surrounding the presence of measles virus in Crohn's disease and concluded …

  • MMR Vaccine: the continuing saga: Current concerns are idiosyncratic: most reviews have confirmed the Vaccine's safety
    BMJ (Clinical research ed.), 2001
    Co-Authors: David Elliman, Helen Bedford
    Abstract:

    The current low uptake of measles, mumps, and rubella (MMR) Vaccine in some parts of the United Kingdom has led to well publicised concerns about the potential for measles outbreaks among primary school entrants. This has coincided with prepublication publicity last week of a paper casting doubts on the adequacy of the evidence which secured the licence for MMR Vaccine.1 Understandably some parents and health professionals are confused and anxious and, in an effort to protect their children against measles, have sought single antigen Vaccines. We have reviewed the latest developments in this saga and are convinced that such confusion and anxiety about MMR Vaccine are unfounded. The authors of the paper, Wakefield and Montgomery, imply that they have examined all the safety data relating to the licensing of the Vaccine1 in the early 1970s (1971 in US and 1972 in UK, not 1975 and 1988 as they say). Although this is their aim, in support of their concerns they also cite studies that postdate the award of licences. Therefore it is surprising that they do not mention the classical Finnish double blind placebo controlled trial among twins.2 This was a rigorous study which reported a low incidence of side effects, including gastrointestinal symptoms. The omission of this important study casts doubt on the completeness and impartiality of their review. The authors pay …